You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
ABT 724 trihydrochloride
Potent dopamine D4 receptor partial agonist (EC50 = 12.4 nM; 61% efficacy vs. dopamine). Has no agonist activity at D2 receptors (EC50 > 10 μM). Selective in rats in vivo; produces penile erection following i.c.v. administration; increases intracavernosal pressure and potentiates the proerectile effects of sildenafil following s.c. administration. Displays minimal side effects.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 402.75. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.48 mL||12.41 mL||24.83 mL|
|5 mM||0.5 mL||2.48 mL||4.97 mL|
|10 mM||0.25 mL||1.24 mL||2.48 mL|
|50 mM||0.05 mL||0.25 mL||0.5 mL|
References are publications that support the biological activity of the product.
Stewart et al (2004) DA D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning. J.Med.Chem. 47 2348 PMID: 15084133
Cowart et al (2004) Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a DArgic agent with a novel mode of action for the potential treatment of erectile dysfunction. J.Med.Chem. 47 3853 PMID: 15239663
Brioni et al (2004) Activation of DA D4 receptors by ABT-724 induces penile erection in rats. Proc.Natl.Acad.Sci.USA 101 6758
If you know of a relevant reference for ABT 724 trihydrochloride, please let us know.
View Related Products by Product Action
Keywords: ABT 724 trihydrochloride, ABT 724 trihydrochloride supplier, Potent, selective, D4, partial, agonists, proerectile, Dopamine, Receptors, dopaminergic, ABT724, trihydrochloride, 2214, Tocris Bioscience
Citations for ABT 724 trihydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for ABT 724 trihydrochloride. Do you know of a great paper that uses ABT 724 trihydrochloride from Tocris? Please let us know.
Reviews for ABT 724 trihydrochloride
There are currently no reviews for this product. Be the first to review ABT 724 trihydrochloride and earn rewards!
Have you used ABT 724 trihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.